Phase 2 Study of NX9 for Delineation of Bowel Anatomy

NCT04789200 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

GI Carcinoma
GI Disorders

Interventions

DRUG: NX9 Oral Contrast Agent

Sponsor

Nextrast, Inc.

Collaborators

[object Object]